非小细胞肺癌组织CD137L表达及其临床意义  

Expression of CD137L in non-small cell lung cancer tissues and its clinical significance

作　　者：承婷[1] 刘怡茜[1] 武常玲[1] 蒋倩[1] 束永前[1] 

机构地区：[1]南京医科大学第一附属医院肿瘤科,江苏南京210029

出　　处：《中华肿瘤防治杂志》2012年第7期506-509,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:观察人非小细胞肺癌(NSCLC)组织中CD137L的表达,探讨CD137L与NSCLC临床病理参数和预后的关系。方法:采用免疫组织化学技术分析61例NSCLC组织中CD137L的表达。将免疫组化检测结果与患者的临床病理特征以及生存时间进行统计学分析。结果:CD137L阳性表达定位于细胞质,部分位于细胞核。在NSCLC组织中的阳性表达率为45.90%(28/61),统计学分析显示,NSCLC组织CD137L表达与年龄、性别和病理类型等无明显相关性(P>0.05),而与临床分期相关(P=0.027),且CD137L表达阳性患者生存期较表达阴性患者延长,P=0.023。结论:CD137L在NSCLC组织中有表达,其阳性表达率可能与临床分期相关;CD137L阳性表达与患者预后呈正相关,对判断NSCLC的预后有一定的参考价值。OBJECTIVE： To observe the expression of CD137L in non-small cell lung cancer （NSCLC） tissues and find the relationship between CD137L and clinieopathological factors, further to analyse the association of CD137L with prognosis of non-small cell lung cancer. METHODS： Immunohistochemmistry was used to detect the expression of CD137L in 61 cases of human non-small cell lung cancer. Then the association among the expression of CD137L and clinicopathalogic variables and overall survival of NSCLC was analyzed. RESULTS： The expression of CD137L protein was observed in cytoplasm, partly in the nucleus. The positive rates of CD137 were 45.90% （28/61）, which were no correla tion with the age, gender, the pathology types and so on（P〈0.05）, but with clinical stage（P=0. 027）. Statistically, the patients with positive expression of CD137L protein had a longer survival time（P=0. 023）. CONCLUSIONS： The expression of CD137L is detected in NSCLC and＇it is associated with clinical stage. The positive expression of CD137L protein positively correlated with prognosis, and it may have some reference value for prognosis of NSCLC.

关 键 词：癌 非小细胞肺 CD137L 免疫组化 生存 

分 类 号：R734.2[医药卫生—肿瘤]